According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...
SmartCella has secured exclusive rights to advance research around cell replacement therapies for the treatment of ...
PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...
AI could deliver substantially greater efficiencies in cell and gene therapy manufacturing and enable more patients to ...
Cell therapy production processes tend to evolve as the ... “One of the technical challenges during scale up is that the process developed to manufacture trial supplies is almost always ...
PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points PHC has ...
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality ...
Pluristyx, the leading provider of innovative induced pluripotent stem cells (iPSC), announces the issuance of the groundbreaking induced Allogeneic Cell Tolerance (iACT Stealth™) U.S. Patent No.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback